HALO Stock Analysis: Buy, Sell, or Hold?
HALO - Halozyme Therapeutics, Inc.
$103.12
17.36 (20.24%)
▲
5d:
+24.93%
30d:
+31.16%
90d:
+58.18%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When HALO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: HALO is 20.4% above its trading range ($85.64). Market expects 4.0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: HALO is 20.4% above its trading range ($85.64). Market expects 4.0% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$142.59
Based on 13.7% avg growth
INTRINSIC VALUE TODAY
$88.54
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HALO is currently trading at $103.12, which is considered extended relative to its 30-day fair value range of $75.69 to $85.64. From a valuation perspective, the stock is trading at a premium (Forward PE: 8.6) compared to its historical average (7.6). At these levels, the market is pricing in 4.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is approaching resistance at $102.41. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 20.2% recently.
Market Sentiment: HALO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HALO is in a strong uptrend. The price is approaching resistance at $102.41. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 20.2% recently.
Market Sentiment: HALO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$75.69 -
$85.64
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
53.3%
Protect Your Profits
HALO is technically overbought (RSI 87). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+20.4% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+20.2%)
- NEUTRAL: Near Wall St target ($86.89)
- NEUTRAL: Market pricing in 4.0% annual earnings growth - fairly valued
- WARNING: Recommendation downgraded due to 20.4% overvaluation
Trading Range Analysis
30-Day Trading Range
$75.69 -
$85.64
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$81.21
Resistance Level
$102.41
Current Trend
Strong Uptrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.59
Wall Street Target
$86.89
(+1.3%)
Revenue Growth (YoY)
42.2%
Earnings Growth (YoY)
31.2%
Profit Margin
23.1%
Valuation Premium vs History
+4.0% premium
PE vs Historical
8.6 vs 7.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.0%
(market-implied from PE analysis)
1-Year Target
$89.19
(+4%)
2-Year Target
$92.76
(+8%)
3-Year Target
$96.47
(+13%)
3-Yr Target (if PE normalizes)
(PE: 9→8)
PE COMPRESSION
$85.36
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 23.3%)
$378.36
(+341%)
Base:
(SPY PE: 8.6, Growth: 23.3%)
$160.63
(+87%)
Bear:
(PE: 7.3, Growth: 23.3%)
$136.54
(+59%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (29x PE), but valuation improves significantly next year (9x PE) as earnings recover.
Trailing PE: 29.23 | Current EPS (TTM): $2.86
Bull Case
$183.90
(+114%)
Analyst growth 100.0%, PE expands to 32.2
Base Case
$167.18
(+95%)
Market implied 100.0%, PE stable at 29.2
Bear Case
$56.84
(-34%)
Severe decline -20.0%, PE contracts to 24.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: August 07, 2026 4:08 PM ET
Data refreshes hourly during market hours. Next update: 5:08 PM
Data refreshes hourly during market hours. Next update: 5:08 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HALO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Helen Torley
SELL
10000 shares
2026-04-06
Helen Torley
SELL
20000 shares
2026-04-02
Cortney Caudill
SELL
8857 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 48 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$23 | 50 HOLD |
Advanced HALO Option Strategies
Professional options setups generated by AI based on today's HALO price and gamma walls.
